NeuroPace Inc

NPCE

NeuroPace Inc

NPCE

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2025-12-15Shares Purchased (TTM):0Shares Sold (TTM):25,000

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:25,855,177Shares Outstanding:33,716,813Institutional Ownership Pct.:76.68%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	13	15	22	21	23	27	13	15	13	13	18	10
Short Term Investments	39	39	39	39	39	39	39	41	43	46	48	52
Accounts Receivable Net Current	15	15	15	15	14	15	13	12	11	12	12	11
Inventory Net	18	17	17	18	16	14	13	12	11	11	11	10
Prepaid Expense And Other Assets Current	1	2	1	2	2	2	2	2	2	2	3	2
Assets Current	86	87	94	95	94	97	81	83	80	84	93	84
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	9	10	10	11	11	11	12	12	13	13	13	14
Restricted Cash Noncurrent	0	1	0	0	0	0	0	0	0	0	0	0
Deferred Costs	-	-	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	97	99	106	107	106	110	95	96	94	99	108	99
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	5	2	5	5	4	3	2	2	3	2	1
Accrued Liabilities Current	11	9	13	12	10	8	10	10	8	7	11	10
Operating Lease Liability Current	2	2	2	2	2	2	2	2	2	2	2	2
Contract With Customer Liability Current	0	0	0	1	1	1	1	1	1	1	1	-
Liabilities Current	17	16	18	20	17	15	15	15	13	13	16	13
Long Term Debt Noncurrent	59	59	59	59	59	60	60	59	59	58	57	56
Operating Lease Liability Noncurrent	9	9	10	10	11	11	12	12	13	13	14	14
Liabilities	85	84	87	89	87	86	87	86	85	85	87	83
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	577	574	571	568	566	562	539	535	530	527	524	514
Retained Earnings Accumulated Deficit	-565	-559	-552	-550	-546	-538	-531	-526	-520	-513	-504	-498
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	-	-	-	-	-	-	0	0
Stockholders Equity	12	14	19	19	19	24	8	10	10	14	21	16
Liabilities And Stockholders Equity	97	99	106	107	106	110	95	96	94	99	108	99
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	34	34	34	33	33	33	30	30	29	29	28	26
Shares Outstanding	34	34	34	33	33	33	30	30	29	29	28	26

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-0.38%	2.15%	-12.97%	-	-	-	-	-	-	-	-	-
2025	1.54%	-19.77%	-30.58%	6.57%	19.61%	8.87%	74.04%	70.43%	77.77%	-3.62%	21.48%	22.34%
2024	-45.16%	-40.00%	-36.83%	-1.10%	-6.18%	-13.60%	57.98%	62.04%	92.72%	-0.59%	-6.50%	48.32%
2023	-	-	-	-	-	-	23.61%	43.19%	102.36%	-7.04%	-5.70%	-46.97%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.94	5.38	5.28	4.86	5.47	6.63	5.37	5.59	6.37	6.43	5.71	6.55
Quick Ratio	3.82	4.25	4.25	3.82	4.42	5.55	4.33	4.63	5.31	5.38	4.85	5.67
Working Capital	68.76M	70.81M	76.26M	75.72M	76.60M	82.77M	66.18M	67.81M	67.64M	71.14M	76.49M	71.16M
Leverage & Debt
Debt to Equity	7.16	5.84	4.55	4.79	4.46	3.54	10.81	8.80	8.55	5.89	4.21	5.07
Interest Coverage TTM	-2.17	-2.46	-2.19	-2.43	-2.47	-2.22	-2.46	-2.61	-2.80	-3.00	-3.19	-3.89
Debt Ratio	0.88	0.85	0.82	0.83	0.82	0.78	0.92	0.90	0.90	0.85	0.81	0.84
Efficiency & Turnover
Asset Turnover TTM	1.01	0.95	1.00	0.89	0.84	0.81	0.79	0.78	0.73	0.67	0.59	0.55
Days Sales Outstanding TTM	50.54	55.42	50.25	53.23	53.52	58.59	57.48	54.52	56.20	55.02	55.22	58.07
Receivables Turnover TTM	7.22	6.59	7.26	6.86	6.82	6.23	6.35	6.69	6.49	6.63	6.61	6.29
Per Share Metrics
Diluted EPS TTM	-0.56	-0.64	-0.66	-0.72	-0.79	-0.79	-0.93	-0.95	-1.04	-1.11	-1.27	-1.46
Free Cash Flow Per Share TTM	-0.38	-0.29	-0.35	-0.27	-0.27	-0.58	-0.63	-0.57	-0.60	-0.62	-0.77	-0.94
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	78.38%	78.29%	77.23%	78.06%	77.07%	74.83%	73.94%	73.83%	74.15%	73.97%	73.56%	72.06%
Operating Profit Margin TTM	-13.33%	-16.84%	-16.34%	-21.56%	-25.11%	-22.86%	-27.12%	-30.17%	-34.50%	-38.22%	-41.54%	-53.13%
Net Profit Margin TTM	-18.58%	-21.67%	-21.47%	-26.40%	-30.68%	-29.42%	-33.97%	-36.74%	-41.63%	-45.61%	-50.38%	-62.96%
Growth Metrics
Net Revenue Growth (1Y)	21.65%	18.06%	25.13%	18.83%	17.73%	22.05%	22.14%	27.00%	30.75%	42.07%	43.72%	37.66%
Net Income Growth (1Y)	-26.32%	-13.06%	-20.91%	-14.61%	-13.23%	-21.27%	-17.64%	-25.89%	-29.54%	-31.50%	-30.00%	-18.72%
EPS Growth (1Y)	-29.00%	-18.83%	-29.60%	-24.12%	-23.81%	-29.26%	-26.90%	-34.51%	-37.80%	-39.22%	-33.41%	-22.74%
Valuation Metrics
P/E TTM	-28.35	-20.56	-23.54	-14.24	-14.11	-15.60	-12.01	-7.31	-7.30	-11.85	-8.09	-6.68
P/B TTM	45.60	30.67	26.55	18.45	18.83	15.94	40.67	20.89	22.07	26.03	12.90	15.47
P/S TTM	5.27	4.45	5.05	3.76	4.33	4.59	4.08	2.68	3.04	5.41	4.07	4.21
Market Cap	541.92M	443.38M	505.23M	341.62M	366.09M	386.90M	325.92M	205.23M	218.13M	373.36M	266.53M	253.15M
Enterprise Value	588.15M	486.77M	542.30M	379.60M	401.73M	419.55M	371.90M	248.96M	264.18M	418.28M	305.31M	299.20M
Calculated Values
Free Cash Flow TTM	-13.11M	-9.84M	-11.34M	-9.06M	-8.91M	-18.14M	-18.26M	-16.79M	-17.28M	-17.68M	-19.87M	-24.45M
Net Debt	46.24M	43.39M	37.07M	37.98M	35.64M	32.65M	45.97M	43.73M	46.05M	44.92M	38.77M	46.05M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-12-15Sale

Owner: Morrell, Martha

Title: CHIEF MEDICAL OFFICER

Shares: 25,000

Price/Share: $15.97

Value: $399,250.00

Shares Owned: 49,964

Relationship: Officer

Ownership: Direct

2025-05-14Sale

Owner: Orbimed, Advisors Llc, Or…

Title: -

Shares: 168,136

Price/Share: $15.88

Value: $2,669,999.68

Shares Owned: 3,238,199

Relationship: TenPercentOwner

Ownership: Indirect

2025-02-21Sale

Owner: Morrell, Martha

Title: CHIEF MEDICAL OFFICER

Shares: 78,334

Price/Share: $13.72

Value: $1,074,742.48

Shares Owned: 81,993

Relationship: Officer

Ownership: Direct

2025-02-20Sale

Owner: Kck, Ltd.

Title: -

Shares: 5,270,845

Price/Share: $9.40

Value: $49,545,943.00

Shares Owned: -

Relationship: TenPercentOwner

Ownership: Direct

2025-01-30Sale

Owner: Morrell, Martha

Title: CHIEF MEDICAL OFFICER

Shares: 200

Price/Share: $15.00

Value: $3,000.00

Shares Owned: 86,762

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-12-15	Morrell, Martha	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	25,000	15.97	$399,250.00	49,964	4
2025-05-14	Orbimed, Advisors Llc, Or…	TenPercentOwner	-	Indirect	Sale	168,136	15.88	$2,669,999.68	3,238,199	4
2025-02-21	Morrell, Martha	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	78,334	13.72	$1,074,742.48	81,993	4
2025-02-20	Kck, Ltd.	TenPercentOwner	-	Direct	Sale	5,270,845	9.40	$49,545,943.00	0	4
2025-01-30	Morrell, Martha	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	200	15.00	$3,000.00	86,762	4
2025-01-24	Morrell, Martha	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	3,200	15.01	$48,032.00	87,062	4
2024-10-25	Kck, Ltd.	TenPercentOwner	-	Direct	Sale	223,991	5.45	$1,220,750.95	5,270,845	4
2024-10-22	Kck, Ltd.	TenPercentOwner	-	Direct	Sale	4,082	6.09	$24,859.38	5,494,983	4
2024-10-21	Kck, Ltd.	TenPercentOwner	-	Direct	Sale	3,720	6.10	$22,692.00	5,499,065	4
2024-10-17	Kck, Ltd.	TenPercentOwner	-	Direct	Sale	3,294	6.28	$20,686.32	5,507,663	4
2024-10-02	Kck, Ltd.	TenPercentOwner	-	Direct	Sale	3,843	6.87	$26,401.41	5,554,089	4
2024-05-03	Orbimed, Advisors Llc, Or…	TenPercentOwner	-	Indirect	Sale	4,674	14.03	$65,576.22	3,406,335	4
2024-04-24	Orbimed, Advisors Llc, Or…	TenPercentOwner	-	Indirect	Sale	1,781	14.06	$25,040.86	3,435,541	4
2024-04-19	Orbimed, Advisors Llc, Or…	TenPercentOwner	-	Indirect	Sale	18,253	14.02	$255,907.06	3,483,722	4
2024-04-18	Orbimed, Capital Gp Vi Ll…	TenPercentOwner	-	Indirect	Sale	2,623	14.06	$36,879.38	3,501,975	4
2024-04-12	Orbimed, Capital Gp Vi Ll…	TenPercentOwner	-	Indirect	Sale	23,101	14.42	$333,116.42	3,518,967	4
2024-02-05	Morrell, Martha	Officer	Chief Medical Officer	Direct	Sale	3,446	15.17	$52,275.82	77,762	4
2024-02-01	Morrell, Martha	Officer	Chief Medical Officer	Direct	Sale	663	15.04	$9,971.52	95,351	4
2024-01-25	Morrell, Martha	Officer	Chief Medical Officer	Direct	Sale	1	15.00	$15.00	109,199	4
2023-12-27	Morrell, Martha	Officer	Chief Medical Officer	Direct	Sale	13,300	10.12	$134,596.00	110,027	4
2023-12-20	Morrell, Martha	Officer	Chief Medical Officer	Direct	Sale	2,730	10.14	$27,682.20	123,429	4
2023-12-06	Morrell, Martha	Officer	Chief Medical Officer	Direct	Sale	11,005	8.16	$89,800.80	126,159	4
2023-12-01	Kck, Ltd.	TenPercentOwner	-	Direct	Sale	3,241	8.73	$28,293.93	5,593,773	4
2023-11-28	Kck, Ltd.	TenPercentOwner	-	Direct	Sale	4,681	8.75	$40,958.75	5,609,940	4
2023-10-03	Orbimed, Capital Gp Vi Ll…	TenPercentOwner	-	Indirect	Sale	700	9.02	$6,314.00	4,003,967	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

76.68%

Inst. Shares: 25,855,177

Shares Outstanding: 33,716,813

2025-12-31

78.96%

Inst. Shares: 25,838,503

Shares Outstanding: 32,722,438

2025-09-30

77.34%

Inst. Shares: 25,627,087

Shares Outstanding: 33,134,606

2025-06-30

65.97%

Inst. Shares: 21,678,598

Shares Outstanding: 32,863,031

2025-03-31

74.10%

Inst. Shares: 23,327,969

Shares Outstanding: 31,480,911

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	25,855,177	33,716,813	76.68%
2025-12-31	25,838,503	32,722,438	78.96%
2025-09-30	25,627,087	33,134,606	77.34%
2025-06-30	21,678,598	32,863,031	65.97%
2025-03-31	23,327,969	31,480,911	74.10%
2024-12-31	20,779,946	29,126,314	71.34%
2024-09-30	14,766,802	29,444,625	50.15%
2024-06-30	14,338,415	28,853,216	49.69%
2024-03-31	13,129,094	28,285,176	46.42%
2023-12-31	12,533,691	25,851,813	48.48%
2023-09-30	18,018,928	26,017,329	69.26%
2023-06-30	17,486,138	25,472,526	68.65%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

NeuroPace Inc (NPCE) — SEC Financial Statements & Analysis

NeuroPace Inc (NPCE) is a surgical & medical instruments & apparatus company, incorporated in DE. NeuroPace Inc trades on Nasdaq as: NPCE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), NeuroPace Inc reported a 21.65% year-over-year revenue growth, a Gross Profit Margin of 78.38% (TTM), a Debt-to-Equity ratio of 7.16x, a Price-to-Sales (P/S) ratio of 5.27x (TTM), a Price-to-Book (P/B) ratio of 45.60x (TTM), at a market cap of $541.92M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 21.65%
Gross Profit Margin TTM: 78.38%
Debt To Equity: 7.16x
P/S TTM: 5.27x
P/B TTM: 45.60x
Market Cap: $541.92M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is NeuroPace Inc in?

NeuroPace Inc (NPCE) operates in the Surgical & Medical Instruments & Apparatus industry.

What is NPCE's market cap?

NeuroPace Inc (NPCE) has a market capitalization of $541.92M as of 2026-06-30.

What exchange does NPCE trade on?

NeuroPace Inc (NPCE) trades on the Nasdaq.

Where is NeuroPace Inc incorporated?

NeuroPace Inc is incorporated in DE.

NeuroPace Inc

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

NeuroPace Inc (NPCE) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Surgical & Medical Instruments & Apparatus

Wall Street's data.
Main Street's price.

NeuroPace Inc (NPCE) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Surgical & Medical Instruments & Apparatus

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.